medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 6

<< Back Next >>

Ann Hepatol 2015; 14 (6)

The treatment of diabetes mellitus of patients with chronic liver disease

García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Maldonado-Garza HJ, Villarreal-Pérez JZ

Language: English
References: 91
Page: 780-788
PDF size: 104.89 Kb.


ABSTRACT

About 80% of patients with liver cirrhosis may have glucose metabolism disorders, 30% show overt diabetes mellitus (DM). Prospective studies have demonstrated that DM is associated with an increased risk of hepatic complications and death in patients with liver cirrhosis. DM might contribute to liver damage by promoting inflammation and fibrosis through an increase in mitochondrial oxidative stress mediated by adipokines. Based on the above mentioned the effective control of hyperglycemia may have a favorable impact on the evolution of these patients. However, only few therapeutic studies have evaluated the effectiveness and safety of antidiabetic drugs and the impact of the treatment of DM on morbidity and mortality in patients with liver cirrhosis. In addition, oral hypoglycemic agents and insulin may produce hypoglycemia and lactic acidosis, as most of these agents are metabolized by the liver. This review discusses the clinical implications of DM in patients with chronic liver disease. In addition the effectiveness and safety of old, but particularly the new antidiabetic drugs will be described based on pharmacokinetic studies and chronic administration to patients. Recent reports regarding the use of the SGLT2 inhibitors as well as the new incretin-based therapies such as injectable glucagon-like peptide-1 (GLP-1) receptor agonists and oral inhibitors of dipeptidylpeptidase- 4 (DPP-4) will be discussed. The establishment of clear guidelines for the management of diabetes in patients with CLD is strongly required.


REFERENCES

  1. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15: 280-8.

  2. Garcia-Compean D, Jaquez-Quintana JO, Lavalle-Gonzalez FJ, Reyes-Cabello E, Gonzalez-Gonzalez JA, Munoz-Espinosa LE, Vázquez-Elizondo G, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis: A prospective study. Ann Hepatol 2012; 11: 240-8.

  3. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.

  4. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43.

  5. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-8.

  6. García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann Hepatol 2009; 8: 13-20.

  7. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40: 68-76.

  8. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 1999; 22: 756-61.

  9. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-25.

  10. Butt Z, Jadoon NA, Salaria ON, Mushtaq K, Riaz IB, Shahzad A, Hashmi AM, et al. Diabetes mellitus and decompensated cirrhosis: risk of hepatic encephalopathy in different age groups. J Diabetes 2013; 5: 449-55.

  11. Jeon HK, Kim MY, Baik SK, Park HJ, Choi H, Park SY, Kim BR, et al. Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage. Dig Dis Sci 2013; 58: 3335-41.

  12. Huang YW, Wang TC, Lin SC, Chang HY, Chen DS, Hu JT, Yang SS, et al. Increased risk of cirrhosis and its decompensation in chronic hepatitis B patients with newly diagnosed diabetes: a nationwide cohort study. Clin Infect Dis 2013; 57: 1695-702.

  13. Elkrief L, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology 2014; 60: 823-31.

  14. Jáquez-Quintana JO, García-Compean D, González JA, Pérez JZ, González FJ, Espinosa LE, Hernández PL, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011; 10: 56-62.

  15. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-81.

  16. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-5.

  17. García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, González-González JA, Muñoz-Espinosa LE, Villarreal- Pérez JZ, Maldonado-Garza HJ. Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis. World J Gastroenterol 2014; 20: 7011-8.

  18. Hagel S, Bruns T, Herrmann A, Stallmach A, Schmidt C. Abnormal glucose tolerance: a predictor of 30-day mortality in patients with decompensated liver cirrhosis. Z Gastroenterol 2011; 49: 331-4.

  19. Marra F, Bertolani C. Adipokines in the liver disease. Hepatology 2009; 50: 957-69.

  20. Crespo J, Cayón A, Fernández-Gil P, Hernández-Guerra M, Mayorga M, Domínguez-Díez A, Fernández-Escalante JC, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001; 34: 1158-63.

  21. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008; 15: 91-101.

  22. García-Compeán D, Jáquez-Quintana JO, Lavalle- González FJ, González-González JA, Maldonado-Garza HJ, Villarreal-Pérez JZ. Plasma cytokine levels imbalance in cirrhotic patients with impaired glucose tolerance and diabetes mellitus. A prospective study. Ann Hepatol 2014; 13: 403-10.

  23. Anty R, Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepatol Gastroenterol 2011; 35: S10-S20.

  24. Petta S, Torres D, Fazio G, Cammà C, Cabibi D, Di Marco V, Licata A, et al. Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 2012; 55: 1317-23.

  25. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 2012; 221: 496-502.

  26. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008; 7: 148-51.

  27. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, et al. Cardiovascular disease in cirrhosis— a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999; 94: 655-62.

  28. An J, Shim JH, Kim SO, Lee D, Kim KM, Lim YS, Lee HC, et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. Circulation 2014; 130: 1353-62.

  29. Cheruvattath R, Balan V. Infections in patients with endstage liver disease. J Clin Gastroenterol 2007; 41: 403-11.

  30. Sorrentino P, Tarantino G, Conca P, Perrella A, Perella O. Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. Can J Gastroenterol 2004; 18: 381-6.

  31. Scheen AJ. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 2014; 10: 839-57.

  32. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-61.

  33. Gundling F, Seidl H, Strassen I, Haller B, Siegmund T, Umgelter A, Pehl C, et al. Clinical manifestations and treatment options in patients with cirrhosis and diabetes mellitus. Digestion 2013; 87: 75-84.

  34. Kwon SY, Kim SS, Kwon OS, Kwon KA, Chung MG, Park DK, Kim YS, et al. Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 2005; 22: 1530-5.

  35. Gentile S, Turco S, Guarino G, Oliviero B, Annunziata S, Cozzolino D, Sasso FC, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab 2001; 3: 33-40.

  36. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, Ganne-Carrie N, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab 2011; 96: 2601-8.

  37. Zhang X, Harmsen WS, Mettler TA, Kim WR, Roberts RO, Therneau TM, Roberts LR, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 2014; 60: 2008-16.

  38. Ahmadieh H, Samir ST. Liver disease and diabetes: Association, pathophysiology and management. Diabetes Res Clin Pract 2014; 104: 53-62.

  39. Kihara Y, Ogami Y, Tabaru A, Unoki H, Otsuki M. Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose. J Gastroenterol 1997; 32: 777-82.

  40. Zillikens MC, Swart GR, van den Berg JW, Wilson JH. Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Aliment Pharmacol Ther 1989; 3: 453-9.

  41. Gentile S, Guarino G, Romano M, Alagia IA, Fierro M, Annunziata S, Magliano PL, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3: 184-91.

  42. Chan NN, Brain HP, Feher MD. Metformin-associated lactic acidosis: a rare or very rare clinical entity? Diab Med 1999; 16: 273-81.

  43. Edwards CM, Barton MA, Snook J, David M, Mak VH, Chowdhury TA. Metformin-associated lactic acidosis in a patient with liver disease. QJM 2003; 96: 315-6.

  44. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-82.

  45. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-90.

  46. de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, et al. Combination of Nacetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008; 38: 159-65.

  47. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750-8.

  48. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001; 24: 873-88.

  49. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolized by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006; 99: 44-51.

  50. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, Hamdy L. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-54.

  51. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012; 56: 464-73.

  52. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-21.

  53. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann- Heurtier A, Serfaty L, Podevin P, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled. Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-10.

  54. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPARgamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003; 38: 434-40.

  55. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-15.

  56. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf 2012; 11: 597-614.

  57. Bryan J, Crane A, Vila-Carriles WH, Babenko AP, Aguilar- Bryan L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des 2005; 11: 2699-716.

  58. Khan R, Foster GR, Chowdhury TA. Managing diabetes in patients with chronic liver disease. Postgrad Med 2012; 124: 130-7.

  59. Goodman RC, Dean PJ, Radparvar A, Kitabchi AE. Glyburide- induced hepatitis. Ann Intern Med 1987; 106: 837-9.

  60. van Basten JP, van Hoek B, Zeijen R, Stockbrügger R. Glyburide- induced cholestatic hepatitis and liver failure. Case-report and review of the literature. Neth J Med 1992; 40: 305-7.

  61. Dourakis SP, Tzemanakis E, Sinani C, Kafiri G, Hadziyannis SJ. Gliclazide-induced acute hepatitis. Eur J Gastroenterol Hepatol 2000; 12: 119-21.

  62. Chitturi S, Le V, Kench J, Loh C, George J. Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci 2002; 47: 1107-10.

  63. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-83.

  64. Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 2012; 72: 249-72.

  65. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 2002; 41: 471-83.

  66. Hatorp V, Walther KH, Christensen MS, Haug-Pihale G. Single- dose pharmacokinetics of repaglinide in subjects with chronic liver disease. J Clin Pharmacol 2000; 40: 142-52.

  67. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmacol 2000; 40: 634-40.

  68. Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 2013; 9: 17-29.

  69. Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012; 13: 81-99.

  70. Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol 2012; 74: 75-85.

  71. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012; 51: 501-14.

  72. Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 2014; 46: 406-19.

  73. Ohki T, Isogawa A, Iwamoto M, Ohsugi M, Yoshida H, Toda N, Tagawa K, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. Scientific World Journal 2012; 2012: 496453.

  74. Harris KB, McCarty DJ. Efficacy and tolerability of glucagon- like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015; 6: 3-18.

  75. Thompson AM, Trujillo JM. Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes. Ann Pharmacother 2015; 49: 351-9.

  76. Garber AJ. Long-acting glucagon-like peptide receptor agonists. Diabetes Care 2011; 34(Suppl. 2): S279-S284.

  77. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet 2014; 53: 773-85.

  78. Subbarayan S, Kipnes M. Sitagliptin: a review. Expert Opin Pharmacother 2011; 12: 1613-22.

  79. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375-93.

  80. Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2014; 30: 204-21.

  81. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, singledose study. Clin Ther 2011; 33: 1798-808.

  82. Nigro SC, Riche DM, Pheng M, Baker WL. Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes. Ann Pharmacother 2013; 47: 1301-11.

  83. Macha S, Rose P, Mattheus M, Cinca R, Pinnetti S, Broedl UC, Woerle HJ. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab 2014; 16: 118-23.

  84. Letiexhe MR, Scheen AJ, Gerard PL, Bastens BH, Pirotte J, Belaiche J, Lefèbvre PJ. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab 1993; 77: 1263-8.

  85. Petrides AS. Liver disease and diabetes mellitus. Diabetes Rev 1994; 2: 2-18.

  86. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 2005; 60: 469-76.

  87. Kupcova V, Arold G, Roepstorff C, Højbjerre M, Klim S, Haahr H. Insulin degludec: Pharmacokinetic properties in subjects with hepatic impairment. Clin Drug Invest 2014; 34: 127-33.

  88. Merli M, Leonetti F, Riggio O, Valeriano V, Ribaudo MC, Strati F, Tisone G, et al. Glucose intolerance and insulin resistance in cirrhosis are normalized alter liver transplantation. Hepatology 1999; 30: 649-54.

  89. Blanco JJ, Herrero JI, Quiroga J, Sangro B, Gómez-Manero N, Pardo F, Cienfuegos JA, et al. Liver transplantation in cirrhotic patients with diabetes mellitus: midterm results, survival, and adverse events. Liver Transpl 2001; 7: 226-33.

  90. Perseghin G, Mazzaferro V, Sereni LP, Regalia E, Benedini S, Bazzigaluppi E, Pulvirenti A. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 2000; 31: 694-703.

  91. Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther 2014; 40: 686-94.




2020     |     www.medigraphic.com